GI Alliance and Iterative Health Partner to Boost GI Clinical Research
GI Alliance (GIA), a leading physician-led gastroenterology network and a Cardinal Health company, has announced a strategic partnership with Iterative Health, a healthcare technology and services firm that specializes in advancing gastrointestinal (GI) clinical research. This collaboration is designed to expand access to clinical trials within community-based practices, allowing more patients to participate in cutting-edge research without having to travel to large academic centers. The partnership aims to create a global research network focused on gastrointestinal and hepatological diseases, blending GIA’s established clinical expertise with Iterative Health’s innovative infrastructure.
“This partnership is a significant step in our ongoing mission to bring research into everyday GI care,” said Dr. Casey Chapman, Chief Medical Officer of GI Alliance. “By combining GIA’s deep clinical experience with Iterative Health’s advanced technology and infrastructure, we can provide more physicians and patients with the opportunity to participate in groundbreaking clinical trials right in their own communities. This is how we bring the future of GI medicine to the frontlines of patient care.”
The collaboration adds 21 active GIA research sites to Iterative Health’s network, bringing the total number of locations to over 70 in the US and Europe. These sites are currently conducting more than 80 Phase II–IV clinical trials across a variety of GI and hepatology conditions. Through this partnership, Iterative Health will take the lead in managing trial operations across both existing and future research sites. By providing operational expertise and a robust pipeline of clinical trials, the partnership aims to integrate clinical research into everyday care, thereby accelerating the development of new treatments for GI diseases.
“We are thrilled to partner with GI Alliance to create a unique offering in clinical research across the United States,” said Jonathan Ng, Founder and CEO of Iterative Health. “This partnership reflects the evolving landscape of healthcare, where a majority of care for complex chronic diseases, like inflammatory bowel disease (IBD) and non-alcoholic steatohepatitis (NASH), is increasingly being provided in community practices. By teaming up with GIA, we can provide physicians who are passionate about both research and community practice with the best possible infrastructure to lead the development of new GI therapeutics.”
GI Alliance represents more than 1,000 physicians across 400 locations in 20 states, delivering care to millions of patients each year. The organization has consistently prioritized clinical research as a key element of its mission, equipping physicians with the resources and support needed to bring innovative therapies to their patients as part of their regular practice. This new partnership with Iterative Health further reinforces GIA’s commitment to expanding patient access to clinical research opportunities.
“This partnership is a game-changer for both the research and clinical care sectors,” said Dr. Chapman. “By integrating clinical trials into community-based care settings, we can accelerate the development of therapies that will have a direct impact on patients’ lives. This collaboration ensures that clinical trials are more accessible, and that patients receive the best treatment options available.”
The integration of Iterative Health’s technology and research expertise with GIA’s community-based network is set to transform the way GI clinical trials are conducted. It enables faster recruitment of patients, increases the diversity of trial populations, and creates more opportunities for patients to engage with clinical research. This partnership will not only benefit physicians but also pharmaceutical companies, providing them with access to experienced investigators, engaged patient populations, and more efficient pathways to trial success.
Iterative Health, headquartered in Cambridge, Massachusetts, is a leader in healthcare technology, specializing in the use of artificial intelligence and data analytics to improve GI care. The company’s expertise in clinical research and patient engagement helps accelerate patient access to novel therapeutics and supports healthcare providers in delivering high-quality care. Iterative Health’s innovative solutions are already having a significant impact on colorectal cancer screenings, and the company’s mission is to continue driving innovation across the GI landscape.
By combining the strengths of GI Alliance and Iterative Health, the partnership aims to create a scalable, high-performing research ecosystem. This collaboration will foster the development of new GI treatments, improve patient outcomes, and help shape the future of gastrointestinal and hepatological care.
About Iterative Health
Iterative Health is a healthcare technology and services company dedicated to transforming GI care through innovation. With deep expertise in artificial intelligence and clinical research, the company empowers healthcare providers to deliver high-quality care and supports clinical research teams in expanding access to novel therapeutics. Based in Cambridge, Massachusetts, Iterative Health operates across the United States and is committed to advancing patient care through cutting-edge technology and data-driven solutions.
